Skip to main content

Articles

Page 5 of 65

  1. The goal of this observational, open-label, cohort study was to determine whether prophylactic migraine treatment with galcanezumab, a peripherally acting drug, alters the incidence of premonitory symptoms, an...

    Authors: Sait Ashina, Agustin Melo-Carrillo, Ajayi Toluwanimi, Nicolas Bolo, Edina Szabo, David Borsook and Rami Burstein
    Citation: The Journal of Headache and Pain 2023 24:26
  2. Appropriate and timely diagnosis is one of the most important milestones in effective migraine care and is affected by public awareness, access to medical care, health care systems, and physicians’ knowledge. ...

    Authors: Ido Peles, Mohnnad Asla, Mariya Abayev, Michal Gordon, Ali Alhoashle, Victor Novack, Rinat Ribalov, Tamar Lengil, Ron Maor, Mayera Elizur and Gal Ifergane
    Citation: The Journal of Headache and Pain 2023 24:25
  3. Headaches are frequent neurological disorders that are yet to be unveiled and treated comprehensively worldwide. Bearing in mind that the distribution of headache subtypes in neurology clinics (NC) is essentia...

    Authors: H. Genc, B. Baykan, H. Bolay, D. Uluduz, I. Unal-Cevik, N. Kissani, O. Luvsannorov, M. Togha, A. A. Ozdemir and A. Ozge
    Citation: The Journal of Headache and Pain 2023 24:24
  4. Anti-calcitonin gene-related peptide monoclonal antibodies (CGRPmAbs) are a favourable option for patients with migraine who experience distressful headache disability and fail to respond to traditional preven...

    Authors: Keiko Ihara, Seiya Ohtani, Narumi Watanabe, Nobuyuki Takahashi, Naoki Miyazaki, Kei Ishizuchi, Satoko Hori, Ryo Takemura, Jin Nakahara and Tsubasa Takizawa
    Citation: The Journal of Headache and Pain 2023 24:23
  5. Authors: Faisal Mohammad Amin, Roberto De Icco, Mohammad Al-Mahdi Al-Karagholi, Jayachandra M. Raghava, Frauke Wolfram, Henrik B. W. Larsson and Messoud Ashina
    Citation: The Journal of Headache and Pain 2023 24:22

    The original article was published in The Journal of Headache and Pain 2021 22:98

  6. In order to pursue its purpose of reducing the global burden of headache, the Global Campaign against Headache has gathered data on headache-attributed burden from countries worldwide. These data, from the ind...

    Authors: Timothy J. Steiner, Andreas Husøy, Hallie Thomas and Lars Jacob Stovner
    Citation: The Journal of Headache and Pain 2023 24:21
  7. To explore the possibility of further dividing migraine without aura (MWA), 1444 female patients fulfilled the criterion were recruited, and grouped basing on the association of MWA onset with menarche and chi...

    Authors: Xiaolin Wang, Weinan Na, Ying Yang, Wenwen Zhang, Junxia Zhao, Tingting Zhang, Yuanji Zhou, Hua Liu, Dong Zhao and Shengyuan Yu
    Citation: The Journal of Headache and Pain 2023 24:20
  8. Headache during hemodialysis (HDH) is prevalent but not negligible. Despite the high prevalence of dialysis headaches, they have rarely been studied. Therefore, this study aimed to evaluate the prevalence, ris...

    Authors: Ying Yang, Fanchao Meng, Hanyu Zhu, Lei Zhang, Guangshuang Lu, Shaobo Xiao, Jiaji He, Shengyuan Yu and Ruozhuo Liu
    Citation: The Journal of Headache and Pain 2023 24:19
  9. Clinical trials and real-world studies revealed a spectrum of response to CGRP(-receptor) monoclonal antibodies (mAbs) in migraine prophylaxis, ranging from no effect at all to total migraine freedom. In this ...

    Authors: Bianca Raffaelli, Mira Fitzek, Lucas H. Overeem, Elisabeth Storch, Maria Terhart and Uwe Reuter
    Citation: The Journal of Headache and Pain 2023 24:16
  10. Worldwide, far from all of those who would benefit make use of headache services, largely because of clinical, social, and political barriers to access. Identifying the factors contributing to low healthcare u...

    Authors: Thien Phu Do, Mikala Dømgaard, Simon Stefansen, Timothy J. Steiner and Messoud Ashina
    Citation: The Journal of Headache and Pain 2023 24:18
  11. To examine whether white matter hyperintensities (WMHs) and cerebral microbleeds (CMBs) are more prevalent in people with persistent post-traumatic headache attributed to mild traumatic brain injury (TBI), com...

    Authors: Håkan Ashina, Rune H. Christensen, Haidar Muhsen Al-Khazali, Afrim Iljazi, Daniel Tolnai, Anna K. Eigenbrodt, Henrik B. W. Larsson, Henrik W. Schytz, Ulrich Lindberg and Faisal Mohammad Amin
    Citation: The Journal of Headache and Pain 2023 24:15
  12. New daily persistent headache (NPDH) is a rare primary headache that is highly disabling. The pathophysiology of NDPH is still unclear, and we aimed to reveal the underlying mechanism of NDPH through functiona...

    Authors: Xueyan Zhang, Wei Wang, Xiaoyan Bai, Yanliang Mei, Hefei Tang, Ziyu Yuan, Xue Zhang, Zhiye Li, Peng Zhang, Zhangxuan Hu, Yaqing Zhang, Xueying Yu, Binbin Sui and Yonggang Wang
    Citation: The Journal of Headache and Pain 2023 24:14
  13. This study aimed to combine voxel-based morphometry, deformation-based morphometry, and surface-based morphometry to analyze gray matter volume and cortex shape in classical trigeminal neuralgia patients.

    Authors: Xiuhong Ge, Luoyu Wang, Lei Pan, Haiqi Ye, Xiaofen Zhu, Sandra Fan, Qi Feng, Quan Du, Wenhua Yu and Zhongxiang Ding
    Citation: The Journal of Headache and Pain 2023 24:17
  14. The changes in resting-state functional networks and their correlations with clinical traits remain to be clarified in migraine. Here we aim to investigate the brain spatio-temporal dynamics of resting-state n...

    Authors: Yan Zhou, Liusheng Gong, Yushu Yang, Linjie Tan, Lili Ruan, Xiu Chen, Hua Luo and Jianghai Ruan
    Citation: The Journal of Headache and Pain 2023 24:13
  15. Migraine is a complex brain disorder explained by the interaction of genetic and environmental factors. In monogenic migraines, including familial hemiplegic migraine and migraine with aura associated with her...

    Authors: Lou Grangeon, Kristin Sophie Lange, Marta Waliszewska-Prosół, Dilara Onan, Karol Marschollek, Wietse Wiels, Petr Mikulenka, Fatemeh Farham, Cédric Gollion and Anne Ducros
    Citation: The Journal of Headache and Pain 2023 24:12
  16. Several studies have described potential microRNA (miRNA) biomarkers associated with migraine, but studies are scarcely reproducible primarily due to the heterogeneous variability of participants. Increasing e...

    Authors: V. J. Gallardo, J. B. Gómez-Galván, L. Asskour, M. Torres-Ferrús, A. Alpuente, E. Caronna and P. Pozo-Rosich
    Citation: The Journal of Headache and Pain 2023 24:11
  17. Migraine is a disabling neurological disorder with the pathophysiology yet to be understood. The microstructural alteration in brain white matter (WM) has been suggested to be related to migraine in recent stu...

    Authors: Lei Zhao, Wenhui Zhao, Jin Cao and Yiheng Tu
    Citation: The Journal of Headache and Pain 2023 24:10
  18. Migraine prophylactic therapy has changed over recent years with the development and approval of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway. As new therapies emer...

    Authors: Linda Al-Hassany, Hannah S. Lyons, Deirdre M. Boucherie, Fatemeh Farham, Kristin S. Lange, Karol Marschollek, Dilara Onan, Umberto Pensato, Elisabeth Storch, Angelo Torrente, Marta Waliszewska-Prosół and Uwe Reuter
    Citation: The Journal of Headache and Pain 2023 24:9
  19. Headache is the most prevalent neurological manifestation in adults and one of the leading causes of disability worldwide. In children and adolescents, headaches are arguably responsible for a remarkable impac...

    Authors: Agnese Onofri, Umberto Pensato, Chiara Rosignoli, William Wells-Gatnik, Emily Stanyer, Raffaele Ornello, Hui Zhou Chen, Federico De Santis, Angelo Torrente, Petr Mikulenka, Gabriele Monte, Karol Marschollek, Marta Waliszewska-Prosół, Wietse Wiels, Deirdre M. Boucherie, Dilara Onan…
    Citation: The Journal of Headache and Pain 2023 24:8
  20. In an earlier paper, we examined the relationship between headache-attributed disability, measured as proportion of time in ictal state, and lost productivity. In a linear model, we found positive and signific...

    Authors: Andreas Husøy, Zaza Katsarava and Timothy J. Steiner
    Citation: The Journal of Headache and Pain 2023 24:7
  21. Chronic headaches and sports-related concussions are among the most common neurological morbidities in adolescents and young adults. Given that the two can overlap in presentation, studying the effects of one ...

    Authors: Muhammad Ali, Nek Asghar, Theodore Hannah, Alexander J Schupper, Adam Li, Nickolas Dreher, Muhammad Murtaza-Ali, Vikram Vasan, Zaid Nakadar, Husni Alasadi, Anthony Lin, Eugene Hrabarchuk, Addison Quinones, Lily McCarthy, Zerubabbel Asfaw, Jonathan Dullea…
    Citation: The Journal of Headache and Pain 2023 24:6
  22. Many migraine patients do not respond adequately to conventional preventive treatments and are therefore described as treatment/medically resistant or difficult to treat cases. Calcitonin gene-related peptide ...

    Authors: Emma Troy, Arif A. Shrukalla, Alina Buture, Katie Conaty, Esther Macken, Roisin Lonergan, Jane Melling, Niamh Long, Eamonn Shaikh, Kieran Birrane, Esther M. Tomkins, Peter J. Goadsby and Martin H. Ruttledge
    Citation: The Journal of Headache and Pain 2023 24:5
  23. While new genetic analysis methods are widely used in the clinic, few researchers have focused on trigeminal neuralgia (TN) with familial clustering (≥ 2 TN patients in one kindred family). Previous literature...

    Authors: Anni Wang, Zimu Song, Xu Zhang, LiFei Xiao, Yan Feng, Chong Qi, Guohuan Zhang, Jinbo Bai, Yang Liu, Tao Sun, Fangang Meng and Feng Wang
    Citation: The Journal of Headache and Pain 2023 24:4
  24. Despite the pervasiveness of migraine, the underlying pathophysiological mechanisms initiating migraine attacks are far from well understood and are matter of scientific debate.

    Authors: Thien Phu Do, Anders Hougaard, Greg Dussor, K. C. Brennan and Faisal Mohammad Amin
    Citation: The Journal of Headache and Pain 2023 24:3
  25. Sphenopalatine ganglion (SPG) is a peripheral structure that plays an important role in cluster headache (CH). Hence, a reliable method to measure the volume of SPG is crucial for studying the peripheral mecha...

    Authors: Jr-Wei Wu, Shu-Ting Chen, Yen-Feng Wang, Kuan-Lin Lai, Ting-Yi Chen, Shih-Pin Chen, Wei-Ta Chen and Shuu-Jiun Wang
    Citation: The Journal of Headache and Pain 2023 24:2
  26. Migraine is a major health burden worldwide with complex pathophysiology and multifarious underlying mechanisms. One poorly understood issue concerns the early steps in the generation of migraine pain. To eluc...

    Authors: R. Giniatullin and A. Nistri
    Citation: The Journal of Headache and Pain 2023 24:1
  27. Authors: Fumihiko Sakai, Koichi Hirata, Hisaka Igarashi, Takao Takeshima, Takeo Nakayama, Hiromi Sano, Hiroyuki Kondo, Yoshiyuki Shibasaki and Nobuyuki Koga
    Citation: The Journal of Headache and Pain 2022 23:164

    The original article was published in The Journal of Headache and Pain 2022 23:70

  28. Migraine is common among females of reproductive age (estimated prevalence:17–24%) and may be associated with reproductive health through underlying central nervous system excitability, autoimmune conditions, ...

    Authors: Holly M. Crowe, Amelia K. Wesselink, Lauren A. Wise, Susan S. Jick, Kenneth J. Rothman, Ellen M. Mikkelsen, Henrik T. Sørensen and Elizabeth E. Hatch
    Citation: The Journal of Headache and Pain 2022 23:162
  29. Authors: Andreas R. Gantenbein, Reto Agosti, Christian P. Kamm, Gunther Landmann, Niklaus Meier, Gabriele Susanne Merki-Feld, Jens A. Petersen, Heiko Pohl, Philippe Ryvlin, Christoph J. Schankin, Dragana Viceic, Chiara Zecca, Elisabeth Schäfer, Ina Meyer and Michael E. Arzt
    Citation: The Journal of Headache and Pain 2022 23:161

    The original article was published in The Journal of Headache and Pain 2022 23:142

  30. Understanding migraine epidemiology and its burden is crucial for planning health policies and interventions at the local level as well as at the global level. National policies in Israel rely on global estima...

    Authors: Ido Peles, Mohnnad Asla, Mariya Abayev, Michal Gordon, Victor Novack, Rinat Ribalov, Tamar Lengil, Ron Maor, Mayera Elizur and Gal Ifergane
    Citation: The Journal of Headache and Pain 2022 23:160
  31. Migraine involves central and peripheral nervous system mechanisms. Erenumab, an anti-calcitonin gene-related peptide (CGRP) receptor monoclonal antibody with little central nervous system penetrance, is effec...

    Authors: Todd J. Schwedt, Simona Nikolova, Gina Dumkrieger, Jing Li, Teresa Wu and Catherine D. Chong
    Citation: The Journal of Headache and Pain 2022 23:159
  32. New daily persistent headache (NDPH) and chronic migraine (CM) are two different types of headaches that might involve vascular dysregulation. There is still a lack of clarity about altered brain perfusion in ...

    Authors: Xiaoyan Bai, Wei Wang, Xueyan Zhang, Zhangxuan Hu, Yingkui Zhang, Zhiye Li, Xue Zhang, Ziyu Yuan, Hefei Tang, Yaqing Zhang, Xueying Yu, Peng Zhang, Yonggang Wang and Binbin Sui
    Citation: The Journal of Headache and Pain 2022 23:156
  33. Calcitonin gene-related peptide (CGRP) antagonizing drugs represents the most important advance in migraine therapy for decades. However, these new drugs are only effective in 50–60% of patients. Recent studie...

    Authors: Song Guo, Charlotte Ernstsen, Anders Hay-Schmidt, David Møbjerg Kristensen, Messoud Ashina, Jes Olesen and Sarah Louise Christensen
    Citation: The Journal of Headache and Pain 2022 23:155

    The Correction to this article has been published in The Journal of Headache and Pain 2023 24:73

  34. The definitive pathogenic mechanisms underlying chronic migraine (CM) remain unclear. Mounting evidence from functional and structural magnetic resonance imaging (MRI) studies suggests that the caudate nucleus...

    Authors: Ziyu Yuan, Wei Wang, Xueyan Zhang, Xiaoyan Bai, Hefei Tang, Yanliang Mei, Peng Zhang, Dong Qiu, Xue Zhang, Yaqing Zhang, Xueying Yu, Binbin Sui and Yonggang Wang
    Citation: The Journal of Headache and Pain 2022 23:154
  35. The multinational phase 3b DELIVER trial was designed to evaluate the efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures across 17 countries. In the...

    Authors: Piero Barbanti, Peter J. Goadsby, Giorgio Lambru, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul and Bjørn Sperling
    Citation: The Journal of Headache and Pain 2022 23:153
  36. Hypothalamus is a key region in migraine attacks. In addition, women are disproportionately affected by migraine. The calcitonin gene-related peptide (CGRP) system is an important key player in migraine pathop...

    Authors: Aida Maddahi, Lars Edvinsson and Karin Warfvinge
    Citation: The Journal of Headache and Pain 2022 23:152
  37. Cluster headache and migraine are regarded as distinct primary headaches. While cluster headache and migraine differ in multiple aspects such as gender-related and headache specific features (e.g., attack dura...

    Authors: Mohammad Al-Mahdi Al-Karagholi, Kuan-Po Peng, Anja Sofie Petersen, Irene De Boer, Gisela M. Terwindt and Messoud Ashina
    Citation: The Journal of Headache and Pain 2022 23:151
  38. Headache recurrence is a common feature of acute therapies, whether approved or still in development, and continues to be a significant problem for both the patient and the clinician. Further complicating this...

    Authors: Stewart J. Tepper, Jessica Ailani, Sutapa Ray, Joe Hirman, Stephen B. Shrewsbury and Sheena K. Aurora
    Citation: The Journal of Headache and Pain 2022 23:148
  39. Cluster headache is a highly debilitating neurological disorder with considerable inter-ethnic differences. Genome-wide association studies (GWAS) recently identified replicable genomic loci for cluster headac...

    Authors: Shih-Pin Chen, Chia-Lin Hsu, Yen-Feng Wang, Fu-Chi Yang, Ting-Huei Chen, Jia-Hsin Huang, Li-Ling Hope Pan, Jong-Ling Fuh, Hsueh-Chen Chang, Yi-Lun Lee, Hung-Ching Chang, Ko-Han Lee, Yu-Chuan Chang, Cathy Shen-Jang Fann and Shuu-Jiun Wang
    Citation: The Journal of Headache and Pain 2022 23:147
  40. DRAGON was a phase 3, randomised, double-blind, placebo-controlled study which evaluated the efficacy and safety of erenumab in patients with chronic migraine (CM) from Asia not adequately represented in the g...

    Authors: Shengyuan Yu, Byung-Kun Kim, Hebo Wang, Jiying Zhou, Qi Wan, Tingmin Yu, Yajun Lian, Michal Arkuszewski, Laurent Ecochard, Shihua Wen, Fangfang Yin, Zheng Li, Wendy Su and Shuu-Jiun Wang
    Citation: The Journal of Headache and Pain 2022 23:146
  41. Trigeminal neuralgia is a severe facial pain disorder. Microvascular decompression is first choice surgical treatment of patients with classical TN. There exist few prospective studies with an independent eval...

    Authors: Anne Sofie Schott Andersen, Tone Bruvik Heinskou, Per Rochat, Jacob Bertram Springborg, Navid Noory, Emil Andonov Smilkov, Lars Bendtsen and Stine Maarbjerg
    Citation: The Journal of Headache and Pain 2022 23:145
  42. In Woldeamanuel and Oliveira (2022)’s article about the efficacy of exercise in the treatment of migraine, the ranking of the efficacy of strength training (mean difference, − 3.55), aerobic exercise (mean dif...

    Authors: Junhee Han and Soo-Jin Cho
    Citation: The Journal of Headache and Pain 2022 23:144

    The original article was published in The Journal of Headache and Pain 2022 23:134

  43. Deficient endogenous pain modulation has been implicated in the development and exacerbation of chronic orofacial pain. To date, relatively little is known regarding the function of the endogenous pain modulat...

    Authors: Christelle Gremeau-Richard, Paul Pionchon, Aurélien Mulliez, Christian Dualé and Radhouane Dallel
    Citation: The Journal of Headache and Pain 2022 23:143
  44. The fully human monoclonal antibody erenumab, which targets the calcitonin gene-related peptide (CGRP) receptor, was licensed in Switzerland in July 2018 for the prophylactic treatment of migraine.

    Authors: Andreas R. Gantenbein, Reto Agosti, Christian P. Kamm, Gunther Landmann, Niklaus Meier, Gabriele Susanne Merki-Feld, Jens A. Petersen, Heiko Pohl, Philippe Ryvlin, Christoph J. Schankin, Dragana Viceic, Chiara Zecca, Elisabeth Schäfer, Ina Meyer and Michael E. Arzt
    Citation: The Journal of Headache and Pain 2022 23:142

    The Correction to this article has been published in The Journal of Headache and Pain 2022 23:161

  45. HER-MES was the first head-to-head, phase 4 trial to assess the tolerability and effectiveness of erenumab against standard of care treatment (topiramate). This post hoc analysis compared the efficacy of erenu...

    Authors: Marc Ehrlich, Christian Hentschke, Christian Sieder, Monika Maier-Peuschel and Uwe Reuter
    Citation: The Journal of Headache and Pain 2022 23:141